Fusiomica sp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2024-12-19
Share capital
5,100.00 PLN
Activity description

Fusiomica is a protein engineering company specializing in the design of de novo mini-protein binders using advanced generative AI algorithms. They produce ultra-stable, high-affinity proteins that can target disease sites inaccessible to traditional antibodies, offering cost-effective imaging probes, biopharmaceuticals, and diagnostic reagents. The company partners with pharmaceutical, biotech, and diagnostic organizations to create bespoke binders and deliver experimentally validated constructs.

Registered address
ul. Szlak 77/222, 31-153 Kraków, Poland
Email
Electronic delivery address
AE:PL-18155-32764-BCGFU-16

Financials

Financial insight

  • The statement flags a going concern risk.

Filing timeliness

The financial statement for 2025 was filed on time.

  • 202501/07/2026
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Division · Scientific research and development1,510 / 1,943
Top 78%
City · Kraków14,214 / 16,184
Top 88%
Voivodeship · Małopolskie24,850 / 27,774
Top 89%
Country · Poland266,853 / 297,566
Top 90%

Results vs industry

Revenue
This companyUSD 5.26kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -13.71kMedianUSD -1.27kAverageUSD -92.87k
Operating costs
This companyUSD 17.49kMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 48.79kMedianUSD 134.71kAverageUSD 3.04m

Offer

  • Protein design
  • Binder discovery
  • Protein optimisation
  • Experimental validation
  • Diagnostic reagents

Websites

  • fusiomica.comFusiomica | AI-designed proteins for a new era of medicine

Job offers

The company has its own careers page: fusiomica.com.

Authorized Representatives

Michał Biśta age 42 – President of the Management Board
Mark Mcalister – Management Board Member

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

OwnerSharesShare valueStake
50$675.3149.0196%
Mark Mcalister
50$675.3149.0196%
Fundacja Rodzinna Filip Stachura
1$13.510.9804%
Fundacja Rodzinna P89
1$13.510.9804%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2025-01-01.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$20,562
De minimis aid (in accordance with Commission Regulation 2023/2831)
$33,741
De minimis aid (in accordance with Commission Regulation 2023/2831)
$1,331

Competitors

Name
Fly-Gen sp. z o.o.
Thesybin Labs P.S.A.
Oncotherics Poland S.A.
Bioinfo Capital sp. z o.o.
Microbiota Med sp. z o.o.
Poltiss sp. z o.o.
Synerga.Fund S.A.
Spinbionic sp. z o.o.
Refoldit sp. z o.o.
Bioinfobank S.A.

Change history

DateEvent
2026-04-16Share capital increase
2024-12-19Entered in the register

FAQ

Last updated: 2026-07-04